Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether BCX4161 given as a daily oral prophylactic treatment is safe and effective in reducing the number of acute attacks in patients with hereditary angioedema.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: BioCryst Pharmaceuticals

Criteria

Key Inclusion Criteria:

• Written informed consent

• Clinical and laboratory diagnosis of Hereditary Angioedema Type I or II

• An average angioedema attack frequency of 1/week

• Acceptable birth control measures

Key Exclusion Criteria:

• Concurrent use of defined treatments for prophylaxis

• Pregnancy or breast-feeding

• Clinically significant medical condition, laboratory abnormality or medical history